2 results

  • adempas

    (riociguat)
    Bayer HealthCare Pharmaceuticals Inc.
    Adempas is indicated for adults with chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or if inoperable, as well as for pulmonary arterial hypertension (PAH). It improves exercise capacity, WHO functional class, and delays clinical worsening. The drug is effective as monotherapy or in combination with other treatments.

  • verquvo

    (vericiguat)
    Merck Sharp & Dohme LLC
    VERQUVO® is indicated for reducing the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and an ejection fraction less than 45%, following hospitalization for heart failure or outpatient IV diuretics.